now i have time for you Orlando....with this stupid comment...
"Simple formula: poor leadership=declining pps."....
let's remind our 'poor' shareholders of some interesting info by this 'poor leadership'....please pay attention to the underlined info:
Good morning and thank you all for joining today's call. There's a lot to cover
today, and of course, I would like to answer everyone's questions at the end
of my thorough review. The areas I will cover today are Generex and
NuGenerex Immuno-Oncology 5:2 dividends in both companies, Generex's
S-1 and funding, Generex's NASDAQ application which is ongoing,
Generex's spinout of our cancer company, NuGenerex Immuno-Oncology,
Generex's Arizona operations, which includes our modality partnering
business, MSO, and ultimately our HMOs, updates on our acquired, owned
subsidiaries Olaregen and Regentys, MediSource, and Pantheon, and then
lastly, our ALTuCELL closing.
In addition, I would also like to address the two main reasons-- which we've
announced over the last several weeks--about the sharp decline in our stock
price over the last several months. This is important as it has been on
everyone's minds and concern, and I get many calls daily on this subject. And
the two reasons are two actors: one, Creek Mountain, who we paid four
million shares of GNBT stock and Veneto Partners who we paid 8.4 million
shares of stock for a total of 12.4 million shares, which the company has had
to deal with coming into the market all at once and/or illegally and/or with no
regard to Generex and Olaregen shareholders.
And then I'll be happy to take all questions and answer them as fast as I can.
If I can't answer a question, it'll be either because it's a legal matter that
cannot be discussed at this moment or we just don't have a full answer as yet
because either there is more investigating to do or it's an area, legally, we
can't unveil due to disclosing our plans to our litigation and criminal targets.
So, with that said, I would like to start the updates.
So, Item 1: Generex dividend. As you all know, our planned dividend of 5:2
of Generex and 5:2 of NuGenerex Immuno-Oncology has been delayed
again. For our January 3 pay date, now 6th ex date. This delay has been due
to the ongoing approval process by the regulators that supervise public
companies corporate actions in this area, which is known as FINRA.
Our attorneys have been working with FINRA and providing necessary
information and answering all the questions, and we hope to have approval in
the end very, very shortly and in the days to come.
However, we do not know for sure, but we assure all Generex shareholders
we will pay this dividend. That would be definitive. And we would, at least,
let everyone know through PR once it is approved. I'd like to say, personally,
that Generex is sorry for the delay, but is out of our control as the regulators
must do their job and provide these reviews to get ultimate satisfaction from
this process.
This has not only been hard on shareholders, but the company's progress and
initiatives have been halted. For example, our S-1 has been filed and until the
dividend is paid, Generex cannot price the S-1 offering and add an addendum
to the deal structure until this dividend is paid. We are confident this would
be done soon and all of us will benefit.
Let's talk about Item 2, which is our S-1 and our funding. As previously
stated, weeks ago, Generex has complete a $40 million equity line and all the
deal docs have closed; in addition, we raised $2.2 million in a bridge
financing, which the company received for a total of $42,200,000, all which
will be entered into the S-1 registration statement, an addendum within the
equity raise our bankers are facilitating in the coming days and weeks. Please
understand the dividend must be paid for this to be fully executed and
Generex to receive the funding.
In addition, we received an SEC comment letter on what's been filed, to-date,
on that S-1 and the SEC only asked to get the deal that's been filed and we
could not have asked for a better initial outcome.
Let's discuss the NASDAQ application because I also get a lot of calls on
that. The application is still pending and ongoing, and the company needs the
S-1 funding to eliminate this going concern from our lawyers until Generex is
fully-funded. We believe once all the funding is in place, ALTuCELL closes,
and we spin out and unlock the NuGenerex Immuno-Oncology value and it's
listed on the NASDAQ, Generex will be ready to execute on its own
NASDAQ listing. (this one is for you Buildit)
Moving onto Item 4. NuGenerex Immuno-Oncology spin-out. The audits are
nearing completion and the S-1 is almost done for NuGenerex ImmunoOncology. We will be completing the last pieces necessary to list on the
NASDAQ stock exchange in the coming days. We will be announcing board
members and additional management team members,(they are doing that now) which is key and very
important as these new members go into the S-1 when we file it.
The funding necessary for listing has been circled up with interested investors
pending the S-1 deal parameters and our clinical plans have been formulated
with new trials in melanoma and bladder cancers in addition to our most
partnered triple-negative trial as well as our prostate trial.
Item 5. Our Arizona operation is progressing very well and now we're about
ready to close and sign three contracts with two previously announced
clinics--Arizona Endo and Paradise Valley. In addition, we just added
another large clinic with over 32,000 patients for a total patient population of
over 100,000 patients in those three clinics.
We are taking space in these clinics and adding podiatry, ophthalmology,
neurology, cardiology, bariatric services, pharmacies and labs in each of the
three clinics, and with our own doctors and staff to support these modalities I
just mentioned.
As well as services, we've also made the decision to make an offer and to
take over an existing surgical center with four operating rooms, eight pre-op
bases, and eight post-op base. This now will complete our Arizona
infrastructure. And the initial partnerships that will give these modalities the
surgery capabilities from those practices in those three clinics. Once
complete, we would implement our MSL strategy in Arizona, signing up
doctor practices and more clinics so service their patients within the end-use
of starting our own HMO. In the coming days and weeks, we will be
announcing the finalization and closing of these endeavors.
Let's go to our existing acquisitions and subsidiaries. Olaregen, Regentys,
MediSource, and Pantheon.
Olaregen is launching new products in addition to signing up new VA
hospitals in which Excellagen would be sold to treat patient wounds as these
new VA hospitals complete committee approval process. The new products
are Excellagen Aesthetics for cosmetic surgery and dermatology markets, and
our new Olarex Core Tissue. We are very excited to be launching these two
products offers. And to update everyone on Regentys all the necessary
manufacturing testing and trial plans for our liquid hydrogel products for
Crohn's disease _____ [00:11:42] ready to start trials. And we are awaiting
the necessary funding from our S-1 to start these trials. We are very eager to
start this work and we are confident this would add huge value to the future
of Generex. I found this to be the most interesting, and now we have the Indian health added as a bonus.
Pantheon and MediSource have had exponential growth in sales since we
acquired these two businesses and we are very happy both of those
companies are growing under the Generex _____ [00:12:07].(i don't want to go there.....this is just wonderful....DON'T Touch IT)
Item 7. ALTuCELL is scheduled to close as soon as the dividend is paid out
and we can price the S-1 financing. This dividend hold-up now has delayed
this closing and we are in the process of working on an extension with the
company. We are confident this would happen and we can close this last
acquisition within the next 30 days pending the dividend payment and S-1 is
effected to bring in the funding.
Item 8. Now, let me address the stock decline and why this has occurred. As
we've announced, two groups we have acquired assets from sold up to 12.4
million shares of stock. 8.4 million from eight individuals that were members
of NL [?] and 4 million from Creek Mountain from which Generex acquired
the additional 20 percent of Olaregen. Both these groups, over the months,
sold--or are selling--their positions without regard to Generex shareholders.
I'd like to discuss, in detail, both situations and will start with Creek
Mountain.
Generex acquired 20 percent additional stake in Olaregen, 4 million shares of
stock and $2 million in cash in the form of a promissory note. Because of the
way it was funding, every quarter, Creek Mountain has agreed to extend the
promissory note for each quarter and our Qs and Ks highlight these
extensions. So, Generex has never been in default. Creek Mountain agreed to
delays of the dividend as well as to keep their shares and book entry at the
transfer agent until the dividend was completed.
Creek Mountain took their shares out of book entry without alerting Generex
and started selling their stock when the dividend was being conducted. When
this occurred, large blocks of stocks were sold, igniting a panic by GNBT
shareholders and Generex had to investigate and finally found out that it was
Creek Mountain that was selling, which caused Generex to postpone the
dividend. Creek never filed or replied forms alerting shareholders they had
such a large position; the company's belief is that they did not file the 13G so
they can go unnoticed in their selling; otherwise, they would have filed that.
The Creek partners all are very sophisticated investors and they know the
rules. Those rules have all been broken.
Also, Creek had non-public, confidential information as they would give
complete updates each quarter, which was necessary to get the necessary
extension on that promissory note. Who would give an extension if they don't
know the extent of what the company is doing? Creek did.
The 1:1 dividend was changed to the new dividend parameters and postponed
past the agreement dates because of Creek's illegal selling. So, because they
created the postponement and the new configuration, they're not entitled to
the dividends. An example of what they did would be lighting their own
house on fire intentionally, putting an insurance claim in, collecting that
insurance claim, wait a month, and then putting in another claim to the same
fire they started. That's illegal and you're entitled to nothing, same as the
dividends.
Generex reserves all of its legal rights and remedies against Creek Mountain-
-and its partners--and will keep our shareholders updated on our progress.
Let's now go through Veneto Partners. Veneto Partners have also sold their
stock illegally under Rule 144 and have not fully paid for those shares.
Veneto put into unrestrict all 8.4 million shares which Generex rejected, to its
transfer agent. Generex is alerting its transfer agent--as well as the law firms-
-that wrote the opinions that, under Rule 144, all the shares were fully paid
for. As that is not the case, Generex is still owed assets from that sale of those
assets, which improves the G-Pharmacy a 6 percent interest in _____
[00:16:44], a company that is owned, and approximately $2.2 million in cash
and working capital. To-date, Generex has only received the MSO from the
sale.
Generex also filed an 8-K as not receiving all the assets, and those assets
were not delivered to Generex, which those shares paid for. The transfer
agent then went ahead and unrestricted those shares, sent them to the
members, and they also just started shooting the shares into the market
without any regard for the shareholders.
Generex also reserves all legal rights and remedies in this scenario, and we
will be going after each and every one of these people.
only problem I see....is people don't want to do DD....
"Simple formula: poor leadership=declining pps."....
let's remind our 'poor' shareholders of some interesting info by this 'poor leadership'....please pay attention to the underlined info:
Good morning and thank you all for joining today's call. There's a lot to cover
today, and of course, I would like to answer everyone's questions at the end
of my thorough review. The areas I will cover today are Generex and
NuGenerex Immuno-Oncology 5:2 dividends in both companies, Generex's
S-1 and funding, Generex's NASDAQ application which is ongoing,
Generex's spinout of our cancer company, NuGenerex Immuno-Oncology,
Generex's Arizona operations, which includes our modality partnering
business, MSO, and ultimately our HMOs, updates on our acquired, owned
subsidiaries Olaregen and Regentys, MediSource, and Pantheon, and then
lastly, our ALTuCELL closing.
In addition, I would also like to address the two main reasons-- which we've
announced over the last several weeks--about the sharp decline in our stock
price over the last several months. This is important as it has been on
everyone's minds and concern, and I get many calls daily on this subject. And
the two reasons are two actors: one, Creek Mountain, who we paid four
million shares of GNBT stock and Veneto Partners who we paid 8.4 million
shares of stock for a total of 12.4 million shares, which the company has had
to deal with coming into the market all at once and/or illegally and/or with no
regard to Generex and Olaregen shareholders.
And then I'll be happy to take all questions and answer them as fast as I can.
If I can't answer a question, it'll be either because it's a legal matter that
cannot be discussed at this moment or we just don't have a full answer as yet
because either there is more investigating to do or it's an area, legally, we
can't unveil due to disclosing our plans to our litigation and criminal targets.
So, with that said, I would like to start the updates.
So, Item 1: Generex dividend. As you all know, our planned dividend of 5:2
of Generex and 5:2 of NuGenerex Immuno-Oncology has been delayed
again. For our January 3 pay date, now 6th ex date. This delay has been due
to the ongoing approval process by the regulators that supervise public
companies corporate actions in this area, which is known as FINRA.
Our attorneys have been working with FINRA and providing necessary
information and answering all the questions, and we hope to have approval in
the end very, very shortly and in the days to come.
However, we do not know for sure, but we assure all Generex shareholders
we will pay this dividend. That would be definitive. And we would, at least,
let everyone know through PR once it is approved. I'd like to say, personally,
that Generex is sorry for the delay, but is out of our control as the regulators
must do their job and provide these reviews to get ultimate satisfaction from
this process.
This has not only been hard on shareholders, but the company's progress and
initiatives have been halted. For example, our S-1 has been filed and until the
dividend is paid, Generex cannot price the S-1 offering and add an addendum
to the deal structure until this dividend is paid. We are confident this would
be done soon and all of us will benefit.
Let's talk about Item 2, which is our S-1 and our funding. As previously
stated, weeks ago, Generex has complete a $40 million equity line and all the
deal docs have closed; in addition, we raised $2.2 million in a bridge
financing, which the company received for a total of $42,200,000, all which
will be entered into the S-1 registration statement, an addendum within the
equity raise our bankers are facilitating in the coming days and weeks. Please
understand the dividend must be paid for this to be fully executed and
Generex to receive the funding.
In addition, we received an SEC comment letter on what's been filed, to-date,
on that S-1 and the SEC only asked to get the deal that's been filed and we
could not have asked for a better initial outcome.
Let's discuss the NASDAQ application because I also get a lot of calls on
that. The application is still pending and ongoing, and the company needs the
S-1 funding to eliminate this going concern from our lawyers until Generex is
fully-funded. We believe once all the funding is in place, ALTuCELL closes,
and we spin out and unlock the NuGenerex Immuno-Oncology value and it's
listed on the NASDAQ, Generex will be ready to execute on its own
NASDAQ listing. (this one is for you Buildit)
Moving onto Item 4. NuGenerex Immuno-Oncology spin-out. The audits are
nearing completion and the S-1 is almost done for NuGenerex ImmunoOncology. We will be completing the last pieces necessary to list on the
NASDAQ stock exchange in the coming days. We will be announcing board
members and additional management team members,(they are doing that now) which is key and very
important as these new members go into the S-1 when we file it.
The funding necessary for listing has been circled up with interested investors
pending the S-1 deal parameters and our clinical plans have been formulated
with new trials in melanoma and bladder cancers in addition to our most
partnered triple-negative trial as well as our prostate trial.
Item 5. Our Arizona operation is progressing very well and now we're about
ready to close and sign three contracts with two previously announced
clinics--Arizona Endo and Paradise Valley. In addition, we just added
another large clinic with over 32,000 patients for a total patient population of
over 100,000 patients in those three clinics.
We are taking space in these clinics and adding podiatry, ophthalmology,
neurology, cardiology, bariatric services, pharmacies and labs in each of the
three clinics, and with our own doctors and staff to support these modalities I
just mentioned.
As well as services, we've also made the decision to make an offer and to
take over an existing surgical center with four operating rooms, eight pre-op
bases, and eight post-op base. This now will complete our Arizona
infrastructure. And the initial partnerships that will give these modalities the
surgery capabilities from those practices in those three clinics. Once
complete, we would implement our MSL strategy in Arizona, signing up
doctor practices and more clinics so service their patients within the end-use
of starting our own HMO. In the coming days and weeks, we will be
announcing the finalization and closing of these endeavors.
Let's go to our existing acquisitions and subsidiaries. Olaregen, Regentys,
MediSource, and Pantheon.
Olaregen is launching new products in addition to signing up new VA
hospitals in which Excellagen would be sold to treat patient wounds as these
new VA hospitals complete committee approval process. The new products
are Excellagen Aesthetics for cosmetic surgery and dermatology markets, and
our new Olarex Core Tissue. We are very excited to be launching these two
products offers. And to update everyone on Regentys all the necessary
manufacturing testing and trial plans for our liquid hydrogel products for
Crohn's disease _____ [00:11:42] ready to start trials. And we are awaiting
the necessary funding from our S-1 to start these trials. We are very eager to
start this work and we are confident this would add huge value to the future
of Generex. I found this to be the most interesting, and now we have the Indian health added as a bonus.
Pantheon and MediSource have had exponential growth in sales since we
acquired these two businesses and we are very happy both of those
companies are growing under the Generex _____ [00:12:07].(i don't want to go there.....this is just wonderful....DON'T Touch IT)
Item 7. ALTuCELL is scheduled to close as soon as the dividend is paid out
and we can price the S-1 financing. This dividend hold-up now has delayed
this closing and we are in the process of working on an extension with the
company. We are confident this would happen and we can close this last
acquisition within the next 30 days pending the dividend payment and S-1 is
effected to bring in the funding.
Item 8. Now, let me address the stock decline and why this has occurred. As
we've announced, two groups we have acquired assets from sold up to 12.4
million shares of stock. 8.4 million from eight individuals that were members
of NL [?] and 4 million from Creek Mountain from which Generex acquired
the additional 20 percent of Olaregen. Both these groups, over the months,
sold--or are selling--their positions without regard to Generex shareholders.
I'd like to discuss, in detail, both situations and will start with Creek
Mountain.
Generex acquired 20 percent additional stake in Olaregen, 4 million shares of
stock and $2 million in cash in the form of a promissory note. Because of the
way it was funding, every quarter, Creek Mountain has agreed to extend the
promissory note for each quarter and our Qs and Ks highlight these
extensions. So, Generex has never been in default. Creek Mountain agreed to
delays of the dividend as well as to keep their shares and book entry at the
transfer agent until the dividend was completed.
Creek Mountain took their shares out of book entry without alerting Generex
and started selling their stock when the dividend was being conducted. When
this occurred, large blocks of stocks were sold, igniting a panic by GNBT
shareholders and Generex had to investigate and finally found out that it was
Creek Mountain that was selling, which caused Generex to postpone the
dividend. Creek never filed or replied forms alerting shareholders they had
such a large position; the company's belief is that they did not file the 13G so
they can go unnoticed in their selling; otherwise, they would have filed that.
The Creek partners all are very sophisticated investors and they know the
rules. Those rules have all been broken.
Also, Creek had non-public, confidential information as they would give
complete updates each quarter, which was necessary to get the necessary
extension on that promissory note. Who would give an extension if they don't
know the extent of what the company is doing? Creek did.
The 1:1 dividend was changed to the new dividend parameters and postponed
past the agreement dates because of Creek's illegal selling. So, because they
created the postponement and the new configuration, they're not entitled to
the dividends. An example of what they did would be lighting their own
house on fire intentionally, putting an insurance claim in, collecting that
insurance claim, wait a month, and then putting in another claim to the same
fire they started. That's illegal and you're entitled to nothing, same as the
dividends.
Generex reserves all of its legal rights and remedies against Creek Mountain-
-and its partners--and will keep our shareholders updated on our progress.
Let's now go through Veneto Partners. Veneto Partners have also sold their
stock illegally under Rule 144 and have not fully paid for those shares.
Veneto put into unrestrict all 8.4 million shares which Generex rejected, to its
transfer agent. Generex is alerting its transfer agent--as well as the law firms-
-that wrote the opinions that, under Rule 144, all the shares were fully paid
for. As that is not the case, Generex is still owed assets from that sale of those
assets, which improves the G-Pharmacy a 6 percent interest in _____
[00:16:44], a company that is owned, and approximately $2.2 million in cash
and working capital. To-date, Generex has only received the MSO from the
sale.
Generex also filed an 8-K as not receiving all the assets, and those assets
were not delivered to Generex, which those shares paid for. The transfer
agent then went ahead and unrestricted those shares, sent them to the
members, and they also just started shooting the shares into the market
without any regard for the shareholders.
Generex also reserves all legal rights and remedies in this scenario, and we
will be going after each and every one of these people.
only problem I see....is people don't want to do DD....
2
